Anti-Aging · Reference
MOTS-c for Men: What the Research Has Looked At, and What It Is Not
This page covers what MOTS-c is, what research has and has not looked at in men, the questions men most often ask (testosterone, muscle, training, TRT, sport, blood sugar), what a physician rules out first in men over 40, and how Pepti supplies it. The general reference is what is MOTS-c, and the evidence benefit by benefit is in MOTS-c benefits. The companion page for women is MOTS-c for women.
Treatments mentioned
There are no randomised trials of MOTS-c in men or in anyone; the one human finding specific to men is genetic: a 2021 study in Aging reported that an East Asian mitochondrial DNA variant that changes one amino acid in MOTS-c was associated, across three cohorts totalling 27,527 people, with a higher prevalence of type 2 diabetes in men, particularly sedentary men. That describes what a natural variant correlates with, not what an injection does. The rest of the research is mouse and cell work on insulin sensitivity and physical capacity. For men, the practical points are that MOTS-c is not a testosterone booster or an anabolic, that it is named on the WADA Prohibited List at all times, and that anyone on glucose-lowering medication needs to say so. It is a compounded prescription injection that is not FDA approved.
This page covers what MOTS-c is, what research has and has not looked at in men, the questions men most often ask (testosterone, muscle, training, TRT, sport, blood sugar), what a physician rules out first in men over 40, and how Pepti supplies it. The general reference is what is MOTS-c, and the evidence benefit by benefit is in MOTS-c benefits. The companion page for women is MOTS-c for women.
MOTS-c for Men
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has MOTS-c been studied in men? | One genetic association study reporting a finding in men; no treatment trial in either sex | Observational only |
| Insulin sensitivity | Prevented age-related and diet-induced insulin resistance in mice (Cell Metabolism, 2015) | Animal and cell only |
| Physical capacity | Better performance in mice of every age tested (Nature Communications, 2021) | Animal only |
| Exercise and the body's own MOTS-c | A bout of exercise raised MOTS-c in human muscle and blood (Nature Communications, 2021) | Human observational; nobody was given MOTS-c |
| Does it raise testosterone? | Not a hormone or a growth hormone secretagogue; not described as acting on the testosterone axis | Not a testosterone booster |
| Does it build muscle? | Mouse performance work, not muscle-building | Not an anabolic |
| Tested sport | Named under S4.4.1 of the 2026 WADA list as an AMPK activator, prohibited at all times | Clear exclusion |
| Glucose-lowering medication | Insulin-sensitivity mechanism in mice | A reason to raise it at intake |
The honest summary: a coherent preclinical story about metabolism and exercise, one genetic signal in men, and no human trial of the injected peptide.
MOTS-c for Men
What MOTS-c is, in one paragraph
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA rather than in the cell nucleus, identified in a 2015 paper in Cell Metabolism from a group at the University of Southern California. The central mechanism proposed is metabolic: in cells it was reported to slow the folate cycle, letting a molecule called AICAR build up, which activates AMPK, the enzyme cells use as a low-fuel sensor and the same one exercise switches on. Skeletal muscle appeared to be the primary target. A 2018 paper in the same journal reported that under metabolic stress MOTS-c moves into the nucleus and changes which genes are switched on. It is not a classical hormone, not a growth hormone secretagogue like ipamorelin or sermorelin, not a GLP-1 medication and not a stimulant.
MOTS-c for Men
What research has looked at in relation to men
The genetic study in men
This is the one human finding reported specifically in men, and it is worth reading precisely. A 2021 paper in Aging looked at an East Asian mitochondrial DNA variant that changes one amino acid in MOTS-c. Across three cohorts totalling 27,527 people, the variant was associated with a higher prevalence of type 2 diabetes in men, particularly sedentary men, and in mice and cells the variant peptide lost its insulin-sensitising activity.
What it shows. That a natural difference in the MOTS-c sequence tracks with diabetes risk in men, more so in men who do not exercise, and that the altered peptide behaves differently in the lab.
What it does not show. That injecting MOTS-c lowers anyone's diabetes risk, changes glucose, or does anything in men who do not carry the variant. It is an association in a specific population, not a treatment result.
Insulin resistance in mice
In the 2015 Cell Metabolism work, MOTS-c treatment in mice was reported to prevent both age-related insulin resistance and the insulin resistance and weight gain that develop on a high-fat diet. That is the founding line of research and the reason MOTS-c is discussed for metabolic health. It has never been tested as a treatment in people.
Exercise, muscle and age
A 2021 paper in Nature Communications reported better physical performance in treated mice that were young, middle-aged and old, and that intermittent treatment started very late in life was associated with better physical capacity and a longer healthy lifespan. The same paper reported that in humans, a bout of exercise raised the body's own MOTS-c in muscle and blood. That human part is what the body does after exercise; nobody was injected. It is why MOTS-c gets called an "exercise mimetic", a label for a proposed mechanism rather than a demonstrated effect in people.
The other human data
Observational studies measuring natural MOTS-c levels do not line up neatly. A study of 225 people in Qatar (Frontiers in Endocrinology, 2019) reported lower levels in people with type 2 diabetes, while a Chilean study of ten lean and ten obese adults (Journal of Investigative Medicine, 2018) and a 2025 study of 85 adults (Archives of Endocrinology and Metabolism) found similar levels with and without obesity. A modified analogue, CB4211, went through a small company-reported Phase 1 program in adults with obesity and fatty liver disease; it is a different molecule, the results were company announcements rather than a peer-reviewed publication, and the program did not advance beyond Phase 1. None of this reported findings for men separately.
MOTS-c for Men
What changes for men
It is not a testosterone booster
MOTS-c is not described as acting on the testosterone axis. It is not a growth hormone secretagogue and does not act on the pituitary. Low drive, lost muscle and poor recovery can point at genuinely low testosterone, which is a different treatment with its own monitoring. The wider picture is in peptides for men over 40.
It is not an anabolic
Nothing in the MOTS-c research describes it adding muscle or strength the way an anabolic would. The mouse work measured physical performance, and the mechanism is about how muscle uses fuel. Men told that MOTS-c builds muscle are being sold a different drug's story.
It goes with training, or it is a much weaker idea
The mechanism is an exercise-signalling pathway, the mice in the 2021 study were tested on treadmills, and the genetic finding was strongest in sedentary men. Prescribers describe MOTS-c as something taken alongside a training and nutrition plan, not instead of one. A metabolic change from an injection alone is not something the evidence supports.
Tested sport: named and prohibited
This is the most settled fact about MOTS-c, and it matters to the men most likely to ask. The 2026 World Anti-Doping Agency Prohibited List names MOTS-c under S4.4.1, activators of AMP-activated protein kinase, in the same line as AICAR, prohibited at all times, in and out of competition. The 2027 list carries the same entry. USADA has stated it is not eligible for a therapeutic use exemption, and a validated plasma test for it was published in 2019. A prescription does not change any of that. If you are tested by any body, including masters and age-group competition, it is not open to you. See peptides for athletes and do peptides show up on a drug test.
Blood sugar and glucose-lowering medication
Because the founding research is about insulin sensitivity, anyone taking a medication that lowers blood glucose, including insulin, should say so at intake. Shakiness, sweating or confusion are the signs of low blood sugar; treat it the way you have been taught for your diabetes medication, then report it the same day. If you start a new glucose-lowering medication during a course, tell your care team before your next dose. More is in MOTS-c side effects.
Alongside testosterone therapy
No interaction with testosterone has been described, and no study has looked at the combination. List your testosterone prescription, your dose and whoever manages it on your intake. See can you take peptides with testosterone.
Fertility
No study has looked at MOTS-c and fertility in men or women. There is no data either way. If conception is a goal in any timeframe you can name, raise it with your physician before starting. See do peptides affect fertility.
If weight is the real goal
MOTS-c has no human trial with weight as an endpoint. Semaglutide and tirzepatide have large randomised human trials with weight as the primary endpoint, and they are the conversation if weight itself is the problem; see MOTS-c vs semaglutide and MOTS-c vs tirzepatide.
MOTS-c for Men
Men over 40: what a physician rules out first
The complaints men bring to MOTS-c, low energy, a soft middle and slower training, often have causes no vial addresses.
| What it is | How it shows up | Why it comes first |
|---|---|---|
| Obstructive sleep apnoea | Exhaustion, low testosterone, weight gain, high blood pressure | Widely undiagnosed; it suppresses testosterone and destroys deep sleep |
| Impaired glucose tolerance or type 2 diabetes | Fatigue, central weight, poor healing | Changes what can be prescribed, and matters doubly with an insulin-sensitivity mechanism |
| Genuinely low testosterone | Low drive, lost muscle, poor recovery | A different treatment with its own monitoring |
| Thyroid disease | Fatigue, cold intolerance, weight change | Treatable and commonly missed |
| Alcohol intake | Fragmented sleep, low testosterone, central fat | The most common reversible cause, and the least often raised |
| Untreated hypertension or lipids | Nothing, until it does | Erectile difficulty is often the first symptom of vascular disease |
A physician reviewing your intake looks at this list before any peptide.
MOTS-c for Men
What the evidence does not establish
- That injected MOTS-c changes weight, glucose, fitness, muscle or lifespan in men. Those trials have not been run.
- That the genetic finding in sedentary men means extra MOTS-c helps anyone.
- Any effect on testosterone or fertility. None was studied.
- An effect size or a timeline in people.
- Long-term safety over years of use.
- Efficacy for any condition as an approved treatment. MOTS-c is not approved for anything.
MOTS-c for Men
Side effects
| What is reported or relevant | When | What to do |
|---|---|---|
| Injection-site redness, mild soreness, occasional bruising | Most common | Rotate sites between abdomen and thigh |
| Transient jitteriness, a faster pulse or mild light-headedness | The hour or two after a morning dose, mostly early in a course | Usually settles; tell your physician if it does not |
| Shakiness, sweating or confusion while on glucose-lowering medication | Any time | Possible low blood sugar; treat it, then report it the same day |
| Facial or throat swelling, widespread rash, difficulty breathing | Rare | Call 911, then tell your physician |
The published animal work reports MOTS-c as well tolerated. There is no human safety data from trials and no established interaction list, which is why the intake asks for every medication you take. Nothing in the live material suggests the profile differs between men and women.
MOTS-c for Men
Where MOTS-c stands with the FDA
MOTS-c was placed in Category 2 of the FDA's interim 503A list in 2023 and removed from it on 15 April 2026. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7 to 5, with two abstentions, to recommend adding MOTS-c (free base and acetate) to the 503A Bulks List for the nominated uses of obesity and osteoporosis, after the FDA's own reviewers recommended against it, citing the absence of human clinical data. A committee vote is a recommendation; the FDA's final determination is pending. MOTS-c remains legal to prescribe and dispense, and compounded medications are not FDA approved.
MOTS-c for Men
How Pepti supplies MOTS-c
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| MOTS-c | 5 mL vial, 2 mg/mL (10 mg MOTS-c); also a 3 mL Pen cartridge containing 30 mg | Vial: 0.25 mL (25 units) subcutaneously Monday through Friday mornings; 0.5 mg per dose, 20 doses | $259/mo |
| PHYSIQ Blend | 10 mg each of tesamorelin, ipamorelin, AOD-9604 and MOTS-c in 5 mL | Printed on the vial | $289/mo |
| SHRED Blend | 10 mg AOD-9604, 6 mg CJC-1295, 10 mg ipamorelin, 10 mg MOTS-c in 5 mL | Printed on the vial | $279/mo |
| FUSION Blend | 10 mg BPC-157, 10 mg MOTS-c, 10 mg 5-amino-1MQ, 15 mg tesamorelin in 5 mL | Printed on the vial | $279/mo |
On the vial, 0.25 mL at 2 mg/mL is 0.5 mg per dose (math only). Twenty weekday doses is four weeks, which is why refills run every 28 days, one vial per fill. Morning timing places the dose near the day's activity. The Pen is dosed by dial as printed with your prescription, so there is no unit conversion. The blends add growth-hormone-axis peptides, which bring their own considerations, including glucose, and tesamorelin, ipamorelin, CJC-1295 and AOD-9604 are themselves prohibited in tested sport under S2. The arithmetic for each product is in MOTS-c dosage. Your physician sets your directions after reviewing your intake, and they are printed on the vial.
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive as ready-to-use solutions with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
MOTS-c for Men
Where to get MOTS-c prescribed
MOTS-c cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, your medications (especially anything that lowers blood glucose, and any testosterone), whether you are drug tested, your training, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your care team stays reachable for questions and side effects.
Step by step: how to get MOTS-c prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
References
What this is based on.
References
- Lee C, Zeng J, Drew BG et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance · Cell Metab (2015) · PMID 25738459
- Reynolds JC, Lai RW, Woodhead JST et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis · Nat Commun (2021) · PMID 33473109
- Kim KH, Son JM, Benayoun BA et al.. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress · Cell Metab (2018) · PMID 29983246
- Zempo H, Kim SJ, Fuku N et al.. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c · Aging (Albany NY) (2021) · PMID 33468709
- Ramanjaneya M, Bettahi I, Jerobin J et al.. Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects · Front Endocrinol (Lausanne) (2019) · PMID 31214116
- Cataldo LR, Fernández-Verdejo R, Santos JL et al.. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals · J Investig Med (2018) · PMID 29593067
- Lu H, Wei M, Zhai Y et al.. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction · J Mol Med (Berl) (2019) · PMID 30725119
- Ming W, Lu G, Xin S et al.. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation · Biochem Biophys Res Commun (2016) · PMID 27237975
- Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes · Rapid Commun Mass Spectrom (2019) · PMID 30394592
- Ozkaya DY, Haymana C, Demirci I et al.. MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction · Arch Endocrinol Metab (2025) · PMID 41004666
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
MOTS-c for Men, answered.
It has not been tested as a treatment in men or anyone. The one human finding in men is a 2021 genetic study linking a MOTS-c variant to higher type 2 diabetes prevalence in sedentary men. The rest is mouse and cell work on insulin sensitivity and physical capacity.
No. It is not a hormone or a growth hormone secretagogue and is not described as acting on the testosterone axis.
No. It is not an anabolic. The mouse studies measured physical performance and muscle fuel use, not muscle growth.
That is a label for the proposed mechanism, AMPK activation, which exercise also switches on. In humans, exercise raises the body's own MOTS-c; no study has shown an injection reproduces the effects of exercise in people.
Yes. The 2026 WADA Prohibited List names it under S4.4.1 as an AMPK activator, prohibited at all times, USADA has stated it is not eligible for a therapeutic use exemption, and a validated test exists.
No interaction has been described, but the combination has not been studied. List your testosterone prescription and dose on your intake.
Say so at intake. Because the founding research is about insulin sensitivity, glucose-lowering medication matters most. Report any low readings or shakiness, sweating or confusion the same day.
No study has looked. There is no fertility data either way, so raise conception plans with your physician before starting.
It is prescribed to men in that age group for metabolic and training goals, on the strength of animal work. A physician first considers sleep apnoea, glucose, thyroid, testosterone and alcohol, because those explain much of what men over 40 bring.
The same as for anyone: mostly injection-site redness, soreness or bruising, and sometimes transient jitteriness, a faster pulse or light-headedness after a morning dose. Facial or throat swelling or difficulty breathing needs 911.
At Pepti, MOTS-c is $259 a month all-in, covering medication, physician review, refill management and shipping. The blends that contain it run $279 to $289 a month.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.